Skip to main content
Livermore
Livermore
ZHEN

Braidwell LP

SEC CIK
0001920938
Latest filing
Aug 14, 2026

The latest 13F from Braidwell LP covers Q2 2026 (filed Aug 14, 2026): 86 long positions worth $2.70B. The top 10 holdings make up 31.6% of the portfolio, and the largest is Caris Life Sciences, Inc. (CAI) at 5.4%. Livermore has 15 filings on Form 13F from this institution, going back to Q4 2022.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
24
Est. +$350.7M
Added
20
Est. +$196.4M
Reduced
34
Est. −$557.6M
Sold out
26
Est. −$676.4M

Top 5 holdings

Share of this quarter's portfolio value

  1. CAICaris Life Sciences, Inc.
    5.4%$147.1MHistory
  2. HNGEHinge Health, Inc.
    4.1%$110.4MHistory
  3. GKOSGLAUKOS Corp
    3.1%$82.7MHistory
  4. EWTXEdgewise Therapeutics, Inc.
    3.0%$81.1MHistory
  5. SYRESpyre Therapeutics, Inc.
    2.9%$78.1MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. HUMHumana Inc
    +$45.5MNewHistory
  2. ATECAlphatec Holdings, Inc.
    +$37.7MAddedHistory
  3. MAZEMaze Therapeutics, Inc.
    +$34.0MNewHistory
  4. AVTXAvalo Therapeutics, Inc.
    +$30.1MNewHistory
  5. ALMRAlamar Biosciences, Inc.
    +$29.4MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. HUMHumana Inc
    +1.68 pp0.0% → 1.7%History
  2. ATECAlphatec Holdings, Inc.
    +1.30 pp0.8% → 2.1%History
  3. MAZEMaze Therapeutics, Inc.
    +1.26 pp0.0% → 1.3%History
  4. AVTXAvalo Therapeutics, Inc.
    +1.11 pp0.0% → 1.1%History
  5. ALMRAlamar Biosciences, Inc.
    +1.09 pp0.0% → 1.1%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. Guardant Health, Inc.40131MAD1
    −$102.6MSold out
  2. CNTACentessa Pharmaceuticals plc
    −$78.9MSold outHistory
  3. NUVLNuvalent, Inc.
    −$71.8MSold outHistory
  4. CGONCG Oncology, Inc.
    −$66.7MSold outHistory
  5. ARGXArgenx SE
    −$62.4MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. Guardant Health, Inc.40131MAD1
    −3.42 pp3.4% → 0.0%
  2. CNTACentessa Pharmaceuticals plc
    −2.63 pp2.6% → 0.0%History
  3. NUVLNuvalent, Inc.
    −2.39 pp2.4% → 0.0%History
  4. CGONCG Oncology, Inc.
    −2.22 pp2.2% → 0.0%History
  5. ARGXArgenx SE
    −1.46 pp2.1% → 0.6%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$2.70B
−$294.3M (−9.8%) vs. prior quarter
Positions
86
−2 vs. prior quarter
Top 10 concentration
31.6%
Top 10 as share of value
Turnover
19.2%
Q2 2026, one quarter
Average holding period
5.6 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2022), so positions held before then are understated.

13F filings by quarter

15 quarters, going back to Q4 2022. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $3.53B (Q3 2024)

Q4 2022: $2.98BQ1 2023: $3.03BQ2 2023: $3.06BQ3 2023: $3.16BQ4 2023: $2.72BQ1 2024: $3.10BQ2 2024: $3.19BQ3 2024: $3.53BQ4 2024: $3.37BQ1 2025: $2.84BQ2 2025: $2.92BQ3 2025: $3.37BQ4 2025: $3.13BQ1 2026: $3.00BQ2 2026: $2.70B
Q4 2022Q2 2026
13F filings of Braidwell LP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202686$2.70BCAIHNGEGKOSvs. Q1 2026SEC
Q1 2026May 15, 202688$3.00BCAIGuardant Health, Inc.Repligen Corpvs. Q4 2025SEC
Q4 2025Feb 17, 202673$3.13BCAIGuardant Health, Inc.EWTXvs. Q3 2025SEC
Q3 2025Nov 14, 202573$3.37BGuardant Health, Inc.CAINovoCure Ltdvs. Q2 2025SEC
Q2 2025Aug 14, 202555$2.92BGuardant Health, Inc.CAINBIXvs. Q1 2025SEC
Q1 2025May 15, 202564$2.84BGuardant Health, Inc.NovoCure LtdNBIXvs. Q4 2024SEC
Q4 2024Feb 14, 202573$3.37BGuardant Health, Inc.BridgeBio Pharma, Inc.NovoCure Ltdvs. Q3 2024SEC
Q3 2024Nov 14, 202481$3.53BGuardant Health, Inc.BridgeBio Pharma, Inc.NovoCure Ltdvs. Q2 2024SEC
Q2 2024Aug 14, 202475$3.19BGuardant Health, Inc.BridgeBio Pharma, Inc.NovoCure Ltdvs. Q1 2024SEC
Q1 2024May 15, 202470$3.10BGuardant Health, Inc.BridgeBio Pharma, Inc.Exact Sciences Corpvs. Q4 2023SEC
Q4 2023Feb 14, 202472$2.72BGuardant Health, Inc.BridgeBio Pharma, Inc.Ascendis Pharma A/Svs. Q3 2023SEC
Q3 2023Nov 14, 202386$3.16BGuardant Health, Inc.NovoCure LtdAscendis Pharma A/Svs. Q2 2023SEC
Q2 2023Aug 14, 202381$3.06BGuardant Health, Inc.Exact Sciences CorpNovoCure Ltdvs. Q1 2023SEC
Q1 2023May 15, 202381$3.03BGuardant Health, Inc.Exact Sciences CorpNanostring Technologies Incvs. Q4 2022SEC
Q4 2022Feb 14, 202388$2.98BGuardant Health, Inc.Nanostring Technologies IncNovoCure Ltd–SEC